medigraphic.com
ISSN 1527-3172 (Digital)

2021, Número 3-4

<< Anterior Siguiente >>

MEDICC Review 2021; 23 (3-4)


Racotumomab in Non-Small Cell Lung Cancer as Maintenanceand Second-Line Treatment

Cáceres-Lavernia HH, Nenínger-Vinageras E, Varona-Rodríguez, LM, Olivares-Romero YA, Sánchez-Rojas I, Mazorra-Herrera Z, Basanta-Bergolla D, Duvergel-Calderín D, Torres-Cuevas BL, del Castillo-Carrillo C

Idioma: Ingles.
Referencias bibliográficas: 49
Paginas: 21-28
Archivo PDF: 255.81 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. International Agency for Research on Cancer(IARC); World Health Organization (WHO).Lung. Number of deaths in 2020 both sexes, allages [Internet]. Lyon: International Agency forResearch on Cancer (IARC); 2020 Dec [cited 2021 Jan 12]. 2 p. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf

  2. Globocan. Lung Cancer Fact Sheet [Internet].[cited 2021 Jan 12]. Available at: https//gco.iarc.fr/today/fact-Sheets-cancers/

  3. National Health Statistics and Medical RecordsDivision (CU). Anuario Estadístico de Salud2019 [Internet]. Havana: Ministry of PublicHealth (CU); 2020 [cited 2021 Jan 12]. Availableat: https://fi les.sld.cu/bvscuba/fi les/2020/05/Anuario-Electr%c3%b3nico-Espa%c3%b1ol-2019-ed-2020.pdf. Spanish.

  4. National Comprehensive Cancer Network [Internet].Pennsylvania: National ComprehensiveCancer Network (NCCN); c2021. Guidelinesand. Treatment by Cancer Type. NCCN ClinicalPractice Guidelines in Oncology (NCCN Guideline®). Survivorship v.2; [updated 2019 Dec 23;cited 2020 Feb 1]. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

  5. National Cancer Institute [Internet]. Maryland:National Cancer Institute, National Institutes ofHealth (US); c2021. Cancer types. Lung cancer.Health professional. Non-Small Cell Lung CancerTreatment (PDQ®). Maryland: National CancerInstitute; 2021 [updated 2021; cited 2021 Jan 7].Available at: wwwcancergov/cancertopics/pdq/treatment/non-small-celllung/healthprofessional/page2

  6. Wu YL, Planchard D, Lu S, Sun H, YamamotoN, Kim DW, et al. Pan-Asian Clinical PracticeGuidelines for the management of patients withmetastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO,MOS, SSO and TOS. Ann Oncol. 2019 Feb1;30(2):171–210. DOI:10.1093/annonc/mdy554

  7. Chansky K, Detterbeck FC, Nicholson AG, RuschVW, Vallières E, Groome P, et al. The IASLCLung Cancer Staging Project: external validationof the revision of the TNM stage groupingsin the eighth edition of the TNM classifi cation oflung cancer. J Thoracic Oncol [Internet]. 2017 Jul[cited 2021 Jan 15];12(7):1109–21. Available at:http://dx.doi. org/10.1016/j.jtho.2017.04.011

  8. Goldberg SB. PD-1 and PD-L1 inhibitors: activityas single agents and potential biomarkers in nonsmallcell lung cancer. Am J Hematol Oncol. 2015Sep 13;11(9):10–3.

  9. Awad MM, Gadgeel SM, Borghaei H, Patnaik A,Chih-Hsin Yang J, Powell SF, et al. Long-termoverall survival from KEYNOTE-021 Cohort G:Pemetrexed and Carboplatin with or withoutPembrolizumab as fi rst-line therapy for advancednonsquamous NSCLC. J Thorac Oncol [Internet].2021 Jan [cited 2021 Jan 15];16(1):162–8.Epub 2020 Oct 15. Available at: https://doi.org/

  10. 10.1016/j.jtho.2020.09.01510. Brahmer JR, Rodriguez-Abreu D, RobinsonAG, Hui R, Csőszi T, Fülöp A, et Al. Healthrelatedquality of life for pembrolizumab versuschemotherapy in advanced NSCLC with PD-L1TPS ≥50%: data from KEYNOTE-024. J ThoracOncol. 2017 Jan;12(1 Suppl 1):S8–S9.

  11. Neninger E, Díaz RM, de la Torre A, Rives R,Díaz A, Saurez G, et al. Active immunotherapywith 1E10 anti-idiotype vaccine in patients withsmall cell lung cancer: report of a phase I trial.Cancer Biol Ther. 2007 Feb;6(2):145–50.

  12. Vázquez AM, Hernández AM, Macías A, MonteroE, Gómez DE, Alonso DF, et al. Racomumomab:an anti-idiotype vaccine related to N-glycolyl-containinggangliosides- preclinical and clinical data.Front Oncol. 2012 Oct 23;2:150:1–6.

  13. Disposición 1446 - 13 - ANMAT - AdministraciónNacional de medicamentos, Alimentos y TecnologíaMédica (ANMAT) [Internet]. Buenos Aires:Ministry of Health (AR); 2013 Mar 5 [cited 2021Jan 11]. 32 p. Available at: www.unq.edu.ar/advf/documentos/543e96e1e423a.pdf. Spanish.

  14. Evaluación de tecnologías sanitarias. Recomendacionespara la utilización de racotumumab.Racotumomab en cáncer de pulmón guía derevisión rápida [Internet]. Buenos Aires: Ministryof Health (AR); 2013 [cited 2021 Jan 11]. Availableat: http://www.msal.gob.ar/images/stories/bes/graficos/0000000847cnt-001-Racotumomab2013.pdf. Spanish.

  15. Samraj AN, Pearce OMT, Läubli H, CrittendenAN, Bergfeld AK, Banda K, et al. A redmeat-derived glycan promotes infl ammationand cancer progression. Proc Natl Acad SciUSA [Internet]. 2015 Jan 13 [cited 2021 Jan11];112(2):542–7. Available at: www.pnas.org/cgi/doi/10.1073/pnas.1417508112

  16. Segatori VI, Cuello HA, Gulino CA, Albertó M,Venier C, Guthmann MD, et al. Antibody-dependentcell-mediated cytotoxicity induced by activeimmunotherapy based on racotumomab in nonsmallcell lung cancer patients. Cancer ImmunolImmunother. 2018 Aug;67(8):1285–96.

  17. Hernández AM, Rodríguez N, González JE,Reyes E, Rondón T, Griñán T, et al. Anti-NeuGc-GM3 antibodies, actively elicited by idiotypic vaccinationin nonsmall cell lung cancer patients,induce tumor cell death by an oncosis-like mechanism.J Immunol. 2011 Mar 15;186(6):3735–44.Epub 2011 Feb 7.

  18. Hernández AM, Toledo D, Martínez D, Griñán T,Brito V, Macias A, et al. Characterization of theantibody response against neugcgm3 gangliosideelicited in non-small cell lung cancer patientsimmunized with an anti-idiotype antibody. JImmunol. 2008 Nov 1;181(9):6625–34.

  19. Wang Q, Huang H, Zeng X, Ma Y, Zhao X,Huang M. Single-agent maintenance therapy foradvanced non-small cell lung cancer (NSCLC):a systematic review and Bayesian networkmeta-analysis of 26 randomized controlled trials.Peer J. 2016 Oct 20;4:e2550. DOI: 10.7717/peerj.2550

  20. Alfonso S, Valdés-Zayas A, Santiesteban ER,Flores YI, Areces F, Hernández M, et al. A randomized,multicenter, placebo-controlled clinicaltrial of Racotumomab-Alum vaccine as Switchmaintenance therapy in advanced non–small celllung cancer patients. Clin Cancer Res. 2014 Jul15;20(14):3660–71. DOI: 10.1158/1078-0432.CCR-13-1674

  21. Gajdosik Z. Racotumomab-a novel anti-idiotypemonoclonal antibody vaccine for the treatment ofcancer. Drugs Today (Barc). 2014 Apr;50(4):301–7. DOI: 10.1358/dot.2014.50.4.2116670

  22. Center for State Control of Medicines, Equipmentand Medical Devices (CU) [Internet]. Havana:Center for State Control of Medicines, Equipmentand Medical Devices (CU); c2021. Registro.VAXIRA® (Racotumomab). Reg. No.: B-013-001-L03C; [cited 2021 Mar 7]. Available at:https://www.cecmed.cu/registro/rcp/vaxirar-racotumomab. Spanish.

  23. National Cancer Institute, Divison of CancerTreatment and Diagnosis – DCTD [Internet].Maryland: National Institutes of Health (US);c2021. Cancer Therapy Evaluation Program.Common Terminology Criteria for AdverseEvents (CTCAE) v4.0; [updated 2010 Jun 14; cited2016 Feb 1]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40

  24. Oken MM, Creech RH, Tormey DC, Horton J,Davis TE, McFadden ET, et al. Toxicity andresponse criteria of the Eastern CooperativeOncology Group. Am J Clin Oncol. 1982Dec;5(6):649–55.

  25. Grose D, Devereux G, Milroy R. Comorbidity inlung cancer: important but neglected. A reviewof the current literature. Clin Lung Cancer. 2011Jul [cited 2016 Jan 11];12(4):207–11. DOI:10.1016/j.cllc.2011.03.020

  26. Wu YL, Zhou C, Liam CK, Wu G, Liu X, ZhongZ, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analysesfrom the phase III, randomized, open-label,ENSURE study. Ann Oncol [Internet]. 2015 Sep[cited 2021 Jan 11];26(9):1883–9. DOI: 10.1093/annonc/mdv270. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0923-7534(19)31770-3

  27. Zaki M, Dominello M, Dyson G, Gadgeel S,Wozniak A, Miller S, et al. Outcomes of erderlypatiens who receive combined therapy for LANSCLCin elderly patients clinical lung cancer.2017 Jan;18(1):e21–e6. DOI: http://dx.doi.org/10.1016/j.cllc.2016.07.005

  28. García-Campelo R, Bernabé R, Cobo M, CorralJ, Coves J, Dómine M, et al. SEOM clinicalguidelines for the treatment of non-small cell lungcancer (NSCLC) 2015. Clin Transl Oncol. 2015Dec;17(12):1020–9. DOI: 10.1007/s12094-015-1455-z

  29. Alfonso S, Díaz RM, de la Torre A, SantiestebanE, Aguirre F, Pérez K, et al. 1e10 anti-idiotypevaccine in non-small cell lung cancer: experiencein stage IIIb/IV patients. Cancer Biol Ther. 2007Dec;6(12):1847–52.

  30. Planchard D, Popat S, Kerr K, Novello S, SmitEF, Fraive-Finn C, et al. Metastatic non-smallcell lung cancer: ESMO Clinical Practice Guidelinesfor diagnosis, treatment and follow-up. AnnOncol. 2020 Oct 1;29(Suppl 4):iv192–iv237.

  31. Babu KG, Prabhash K, Vaid AK, Sirohi B, DiwakarRB, Rao R, et al. Nimotuzumab plus chemotherapyversus chemotherapy alone in advancednon-small-cell lung cancer: a multicenter, ramdomized,open-label Fase II study. Onco TargetsTher [Internet]. 2014 Jun 13 [cited 2021 Jan11];7:1051–60. Available at: https://www.dovepress.com/

  32. Gómez RE, Alfonso S, Santiesteban ER,Neninger E, Ardigo ML, Vázquez AM, et al.Active immunotherapy in patients with progressivedisease after fi rst line therapy: Racotumomabexperience. J Clin Oncol [Internet]. 2013May 20 [cited 2016 Jan 11];31(15 Suppl):3086.DOI: 10.1200/jco.2013.31.15_suppl.3086. Availableat: https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.3086

  33. Sokolovska A, Hem SL, Hogen Esch H. Activationof dendritic cells and induction of cd4(+) Tcell differentiation by aluminum-containing adjuvants.Vaccine. 2007 Jun 6;25(23):4575–85.

  34. Hernández AM, Vázquez AM. Racotumomab–alum vaccine for the treatment of nonsmall-cell lung cancer. Expert Rev Vaccines.2015 Jan;14(1):9–20. Epub 2014 Nov 25.DOI: 10.1586/14760584.2015.984691

  35. Pérez L, Estévez D, Gastón Y, Macías A, ViadaCE. Seguridad del Racotumomab en el tratamientode pacientes con cáncer de pulmón decélulas no pequeñas. VacciMonitor [Internet].2013 Jan–Apr [cited 2016 Jan 11];22(1):10–4.Available at: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=40754.Spanish.

  36. Viada C, Fors M, Neninger E, Alfonso S, SantiestebanE, Mendoza I, et al. Seguridad de lavacuna anti-idiotípica 1E10 en pacientes contumores de diversas localizaciones. Bionatura[Internet]. 2016 [cited 2021 Jan 11];1(1):14–9.Available at: https://www.revistabionatura.com/files/2-Seguridad-de-la-vacuna-anti-idiotipica-1E10-en-pacientes-Investigacion.pdf. Spanish.

  37. Eurocare-5. European cancer registry-basedstudy on survival and care of cancer patients:Eurocare [Internet]. Rome: Institute of Health(IT); 2017 [cited 2017 Oct 5]. Available at: http://www.eurocare.it/Eurocare5/ResultsEU5/tabid/90/Default.aspx

  38. Hardtstock F, Myers D, Li T, Cizova D, MaywaldU, Wilke T, et al. Real-world treatment and survivalof patients with advanced non-small celllung cancer: a German retrospective data analysis.BMC Cancer [Internet]. 2020 Mar 30 [cited2021 Jan 11];20(1):260. Available at: https://doi.org/10.1186/s12885-020-06738-z

  39. Moro-Sibilot D, Smit E, de Castro Carpeño J,Lesniewski-Kmak K, Aerts J, Villatoro R, etal. Outcomes and resource use of non-smallcell lung cancer (NSCLC) patients treatedwith fi rst-line platinum-based chemotherapyacross Europe: FRAME prospective observationalstudy. Lung Cancer [Internet]. 2015 May[cited 2021 Jan 11];88(2):215–22. Availableat: https://linkinghub.elsevier.com/retrieve/pii/S0169-5002(15)00118-X

  40. Pirker R, Pereira JR, von Pawel J, KrzakowskiM, Ramlau R, Park K, et al. EGFR expression asa predictor of survival for first-line chemotherapyplus cetuximab in patients with advanced nonsmall-cell lung cancer: analysis of data fromthe phase 3 FLEX study. Lancet Oncol. 2012Jan;13(1):33–42. DOI: 10.1016/S1470-2045(11)70318-7

  41. Arnold BN, Thomas DC, Rosen JE, Salazar MC,Blasberg JD, Boffa DJ, et al. Lung cancer in thevery young: treatment and survival in the NationalCancer Date Base. J Thoracic Oncol [Internet].2016 Jul [cited 2021 Jan 11];11(7):1121–31.Available at: http://dx.doi.org/10.1016/j.jtho.2016.03.023

  42. Perol M, Chouaid C, Pérol D, Barlési F, GervaisR, Westeel V, et al. Randomized, phase III studyof gemcitabine or erlotinib maintenance therapyversus observation, with predefi ned second-linetreatment, after cisplatin-gemcitabine inductionchemotherapy in advanced non-small-celllung cancer. J Clin Oncol [Internet]. 2012 Oct1 [cited 2021 Feb 15];30(28):3516–24. Availableat: https://ascopubs.org/doi/10.1200/JCO.2011.39.9782?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  43. Edelman MJ, Le Chevalier T, Soria JC. Maintenancetherapy and advanced non-small-cell lungcancer: a skeptic’s view. J Thorac Oncol [Internet].2012 Sep [cited 2021 Feb 15];7(9):1331–6.Available at: https://linkinghub.elsevier.com/retrieve/pii/S1556-0864(15)32932-4

  44. Patel JD, Socinski MA, Garon EB, ReynoldsCH, Spigel DR, Olsen MR, et al. Point break: arandomized phase III study of pemetrexed pluscarboplatin and bevacizumab followed by maintenancepemetrexed and bevacizumab versuspaclitaxel plus carboplatin and bevacizumab followedby maintenance bevacizumab in patientswith stage IIIB or IV nonsquamous non-smallcelllung cancer. J Clin Oncol [Internet]. 2013Dec 1 [cited 2021 Jan 11];31(34):4349–57.Available at: https://ascopubs.org/doi/10.1200/JCO.2012.47.9626?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  45. Paz-Ares LG, de Marinis F, Dediu M, ThomasM, Pujol JL, Bidoli P, et al. PARAMOUNT: Finaloverall survival results of the phase III studyof maintenance pemetrexed versus placeboimmediately after induction treatment with pemetrexedplus cisplatin for advanced nonsquamousnon-small-cell lung cancer. J Clin Oncol. 2013Aug 13 [cited 2021 Jan 12];31(23):2895–902.Available at: https://ascopubs.org/doi/10.1200/JCO.2012.47.1102?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  46. Shepherd FA, Dancey J, Ramlau R, Mattson K,Gralla R, O’Rourke M, et al. Prospective randomizedtrial of docetaxel versus best supportivecare in patients with non-small-cell lung cancerpreviously treated with platinum-based chemotherapy.J Clin Oncol. 2000 May;18(10):2095–103.

  47. Rittmeyer A, Barlesi F, Waterkamp D, Park K,Ciardiello F, von Pawel J, et al. Atezolizumab versusdocetaxel in patients with previously treatednon-small-cell lung cancer (OAK): a phase 3,open-label, multicentre randomised controlledtrial. Lancet. 2017 Jan 21;389(10066):255–65.DOI: 10.1016/S0140-6736(16)32517-X

  48. Santiesteban E, Pérez L, Alfonso S, NeningerE, Acosta S, Flores Y, et al. Safety and effi cacyof Racotumomab-Alum vaccine as second-linetherapy for advanced non-small cell lung cancer.Int J Clin Med [Internet]. 2014 Jul [cited 2021Jan 12];5(14):844–50. Available at: http://dx.doi.org/10.4236/ijcm.2014.514113

  49. Hernández M, Neninger E, Santiesteban E,Camacho K, Hernández N, Amador R, et al.Effi cacy of racotumomab or nimotuzumab vsdocetaxel as second line therapy for advancednon-small cell lung cancer patients. Ann Oncol.2018 Oct;29(Suppl 8):viii415. DOI:10.1093/annonc/mdy288 | viii415




2020     |     www.medigraphic.com